Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Persevera is a bust, but Roche hasn’t given up on the front line.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
